CorEvitas Announces First Patient Enrollment in a New Biorepository Study focused on Precision Medicine for JAK Inhibitors in Rheumatoid Arthritis
Excerpt from the Press Release:
WALTHAM, Mass., Aug. 10, 2021 /PRNewswire/ — CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries. Eligible rheumatology registry patients will contribute biological specimens that will be linked to longitudinal provider reported clinical and patient reported outcomes.
“We are excited to launch this biospecimen study to help advance the development of personalized therapies and diagnostics for rheumatology patients. We envision that this biospecimen study will enable us to uncover even deeper clinical insights from patients in order to improve care,” said Austin Read, Vice President, Biospecimen Solutions.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?